Active infection requiring systemic therapy
Patients must not have an active infection requiring systemic therapy at time of registration
Patients must not have an active infection requiring systemic therapy
Patients must not have an active infection requiring systemic therapy
Active infection (any infection requiring systemic treatment)
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has a known active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Patient has an active infection requiring systemic therapy
SAFETY RUN-IN: Active infection requiring systemic therapy
Has an active infection requiring therapy.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
An active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection (any infection requiring systemic treatment)
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring therapy.
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic treatment
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring therapy.
Patient has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy; NOTE: when the infection is controlled, patients are permitted for this study
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy at the time of study treatment initiation
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy.
Participants must not have an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection at the time of cycle 1 day 1 requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
active infection requiring systemic therapy;
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Patient has active infection requiring system therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Other active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Any active infection requiring systemic treatment
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Patients active infection requiring intravenous systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy.
Patient has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection, requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Current active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Have an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy or hospital admission
Has an active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy or hospital admission
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring therapy
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic treatment
Any other active malignancy requiring systemic therapy
Active infection requiring systemic therapy
Acute active infection requiring systemic therapy within 2 weeks prior to enrollment
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy or hospital admission
Has an active serious bacterial infection requiring systemic therapy
Subject has an active infection requiring systemic therapy, including active tuberculosis
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring therapy
Patient has an active infection requiring systemic therapy
Active carcinoma requiring systemic chemotherapy or radiation therapy
Active infection requiring systemic therapy.
Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy before Screening is initiated
An active infection requiring systemic IV therapy.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy;
Active infection requiring systemic therapy.
Active infection requiring systemic therapy
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
REGISTRATION TO TREATMENT (STEP 1): Patient must not have an active infection requiring systemic therapy
REGISTRATION TO TREATMENT (STEP 2): Patient must not have an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy
Patient has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active viral infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active or chronic infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Participants with an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic treatment
Has an active infection requiring systemic therapy.
Active infection requiring intravenous systemic therapy.
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Patients must not have an active infection requiring systemic therapy
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy.
Has an active infection requiring therapy.
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy
Presence of active infection requiring systemic therapy
Subject has active infection requiring systemic therapy
Active infection requiring systemic therapy at enrollment
Has an active infection requiring systemic treatment
Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
Has an active infection requiring systemic therapy or uncontrolled infection.
Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
Active infection requiring therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
No active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring IV systemic therapy
Active infection requiring systemic therapy within 14 days
Active infection requiring systemic therapy
Active infection requiring systemic therapy.
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy before Screening
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Ongoing or active infection requiring systemic treatment
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Participant has an active infection requiring therapy.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy (? grade 2) for more than 3 days within 1 week of enrollment.
Active infection requiring systemic therapy
Active infection requiring therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Active infection requiring systemic therapy
Has any active infection requiring systemic therapy
Active infection requiring systemic therapy.
Presence of an active systemic infection requiring treatment.
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy;
Active infection (any infection requiring systemic treatment)
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring therapy
Evidence of active infection requiring systemic therapy
Have an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy.
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
evidence of active infection requiring systemic therapy.
Active infection requiring therapy
Patient has an active systemic infection requiring treatment.
Active, serious infection requiring systemic therapy
Patients with active infection requiring systemic treatment
Has an active infection requiring systemic therapy
Evidence of active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy
Has active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Active infection requiring systemic therapy
Current active infection requiring systemic treatment.
Active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Active infection requiring systemic therapy
Has an active infection requiring systemic treatment
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring intravenous systemic therapy.
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Has an active infection requiring systemic therapy
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before registration
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Patients who have an infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment are not eligible
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring intravenous antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization.
Systemic infection requiring intravenous (IV) antibiotic or antifungal or antiviral therapy within 7 days preceding the first dose of study drug, or other severe infection
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study drug administration
Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment
Serious infection requiring parenteral antibiotic therapy or any other serious infection within 14 days before randomization.
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration
Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to start of study treatment
Infection requiring systemic IV antibiotic therapy within 7 days before cycle 1 day 1 of therapy
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
Infection requiring systemic antibiotic therapy within 14 days prior to the start of study treatment
Infection requiring systemic antibiotic therapy or other serious infection ? 7 days prior to registration
Systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection
Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before first dose of study drug
Serious infection requiring systemic antibiotic therapy within 14 days prior to study treatment.
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection
Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection
Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization.
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment.
Active clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug
Active clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before randomization.
Systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Subject has systemic infection requiring intravenous (IV) antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection
Serious infection requiring intravenous antibiotic therapy within 14 days prior to study treatment
Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment.
Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment.
Infection requiring IV antibiotic therapy or other serious infection within 14 days prior to first dose of study drug
Systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection
Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment. For the HCC, HCC/BTC and BTC subgroups hepatitis C infection and hepatitis B infection if controlled with antiviral therapy are allowable.
Systemic infection requiring intravenous (IV) antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection
Systemic infection requiring parenteral antibiotic therapy or other serious infection (bacterial, fungal, or viral) within 21 days before the first dose of study drug.
Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
Infection requiring systemic antibiotic therapy within 14 days prior to start of study treatment
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment
Systemic infection requiring intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
The subject has or had any active infection requiring systemic antibiotic, antifungal or antiviral therapy within the past 4 weeks
All patients receiving antifungal therapy voriconazole, posaconazole, or fluconazole must have sirolimus reduced according to the Standard Practice Antifungal Therapy Guidelines
Systemic infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration
Have a chronic or active infection that requires systemic antibiotics, antifungal or antiviral treatment
Currently receiving systemic antibiotic, antiviral, or antifungal therapy for the treatment of an active infection
Recent or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment within 2 weeks prior to the start of study drug
Concomitant therapy that includes other chemotherapy that is or may be active against AML except for prophylaxis and/or treatment of opportunistic or other infection with antibiotics, antifungals and/or antiviral agents.
Uncontrolled active infection (bacterial, fungal, viral, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents
Absence of uncontrolled active infection (bacterial, fungal, viral, mycobacterial) not responding to treatment with antibiotics, antiviral agents, or antifungal agents
Off antibiotic/antifungal therapy for >/=14 days (Cohort C)
Has active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) ? 10 days of C1D1
Active clinically serious infections requiring antibiotics, antiviral or antifungal agents; participants must be off these agents for at least 28 days prior to the first dose of the study drug
Active infection requiring antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patient’s ability to tolerate therapy
Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
EXCLUSION CRITERIA FOR TNBC: Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
Has active, serious infection requiring systemic therapy. Patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the treating physician.
Patient has or had any active infection requiring antibiotic, antifungal, or antiviral therapy within the 2 weeks prior to administration of Toca 511.
Any ongoing infection whether receiving or not receiving antibiotics or have received intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the start of the study drug.
Active (uncontrolled) infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents (excluding HIV)
Active, systemic infection requiring intravenous (IV) antibiotic, antifungal, or antiviral therapy or other serious infection within 14 days before the first dose of study drug.
Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush
Acute active infection requiring intravenous antibiotics, antiviral (except antiviral directed at hepatitis B), or antifungal agents within 14 days of first dose
Receipt of any systemic (oral, intravenous, or inhaled) antifungal therapy for this infection episode for 4 or more consecutive days (>= 96 hours) immediately before randomization.
Developed the current episode of IA infection during receipt of >13 days of antifungal prophylaxis with an agent considered to be a mold-active antifungal agent.
Chronic or current active infection requiring systemic antibiotic, antifungal, or antiviral treatment
Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments
Presence of a fungal infection requiring systemic antifungal treatment at enrollment
Serious, uncontrolled infection requiring systemic antibiotic, antifungal or antiviral therapy. Prophylactic antibiotic, antifungal and/or antiviral therapy is permitted
Patients with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent)
Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment (defined as requiring IV antimicrobial, antifungal or antiviral agents) ( Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met and there is no evidence of active infection at Screening and/or Cycle 1 Day 1 (predose))
Active infection requiring antibiotic, antiviral, or antifungal treatment.
Per PI discretion, active infection that is not well controlled by antibacterial or antiviral therapy.
Received > 24 hours of systemic antibacterial therapy within 72 hours of the initiation of inpatient IV study drug for treatment of suspected infection; antibiotic prophylaxis is allowed; prophylactic use of antiviral or antifungal medication is permitted
Acute infection requiring intravenous antibiotics, antiviral or antifungal agents during the 14 days prior to first dose of rucaparib
Active infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents (excluding HIV)
Treatment with appropriate antiviral therapy for patients with active HBV infection is required
Active infection not well controlled by antibacterial or antiviral therapy.
Currently active and uncontrolled infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
History of chronic or recurrent infections that require continual use of antiviral, antifungal, or antibacterial agents.
Uncontrolled infection; to be eligible, patients receiving treatment for an infection (antibiotic, antifungal or antiviral treatment) must be afebrile (< 38.3 degrees Celsius [C]) and without hemodynamic instability or dyspnea from pneumonia for > 48 hours (hrs) prior to the start of induction therapy
Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments
Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ?14 days before the first dose of study drug.
Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment (defined as requiring IV antimicrobial, antifungal or antiviral agents) ? Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met and there is no evidence of active infection at randomization
Active infection requiring IV antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patient’s ability to tolerate therapy
Active or uncontrolled infection. Patients with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ?72 hrs.
All patients receiving antifungal therapy voriconazole, posaconazole, or fluconazole and who are then randomized to ARM 2 must have sirolimus reduced according to the Standard Practice Antifungal Therapy Guidelines
Invasive fungal or viral infection not responding to appropriate antifungal or antiviral therapies.
Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
Evidence of significant active infection requiring antimicrobial, antifungal, antiparasitic, or antiviral therapy or for which other supportive care is given
Patients with an active infection that requires systemic antibiotics, antiviral, or antifungal treatments
Ongoing systemic bacterial, fungal, or viral infections at randomization (defined as requiring IV antimicrobial, antifungal or antiviral agents)
Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other I/E criteria are met
Serious, uncontrolled infection requiring systemic antibiotic, antifungal or antiviral therapy
Active infection requiring systemic antibacterial/antibiotic, antifungal, or antiviral therapy.
Active or uncontrolled infection. Patients with any infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ?72 hrs. Patients with fevers believed to be due to leukemia or MDS are eligible provided a thorough infection work-up is negative and the patient is clinically and hemodynamically stable.
Does the subject have, or has the subject had, within the past 4 weeks any infection requiring antibiotic, antifungal or antiviral therapy?
Acute active infection requiring systemic antibiotics, antiviral (except antiviral directed at hepatitis B) or antifungal agents within 14 days of first dose
Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening.
Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B) or antifungal agents within 14 days prior to randomization.
Active systemic viral, bacterial, or fungal infection requiring antimicrobial, antiviral therapy or antifungal therapy within 2 weeks prior to the first dose of study drug (routine antimicrobial prophylaxis is acceptable)
Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments
Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
The participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy.
Known active infections requiring IV antibiotic, antiviral, or antifungal therapy.
Active or uncontrolled infection. Patients with any infection receiving treatment (antibiotic,antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ?72 hrs. Patients with fevers believed to be due to leukemia or MDS are eligible provided a thorough infection work-up is negative and the patient is clinically and hemodynamically stable.
Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;
Use of systemic antibacterial, antifungal, or antiviral medications for the treatment of acute clinically significant infection within 2 weeks of first veledimex dose. Concomitant therapy for chronic infections is not allowed. Subjects must be afebrile prior to Ad-RTS-hIL-12 injection; only prophylactic antibiotic use is allowed perioperatively
Have a chronic or active infection that requires systemic antibiotics, antifungal or antiviral treatment
Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment, except concomitant antiviral systemic therapy for chronic hepatitis B or C.
Active uncontrolled infection [i.e., antibiotic, antifungal or antiviral intervention indicated or surgical procedure (i.e., pleural or deep abscess drainage) conducted within 15 days prior to inclusion].
No active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician)
Active systemic infection requiring parenteral antibiotic therapy; all prior infections must have resolved following optimal therapy
Active infection requiring systemic antibiotic therapy.
Active infection requiring systemic antibiotic therapy
Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy
Active infection requiring systemic antibiotic therapy.
Subjects with active infection requiring antibiotic therapy
Active infection requiring systemic antibiotic therapy
Active infection requiring systemic antibiotic therapy.
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Has an active infection requiring systemic antibiotic therapy at time of enrollment\r\n* Treatment with antibiotic prophylaxis for indwelling biliary stent(s) or peri-procedural antibiotics for uncomplicated biliary stent exchanges is allowed and not an exclusion
Active infection requiring systemic antibiotic therapy
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Active infection requiring systemic antibiotic therapy.
EXCLUSION - PARTICIPANT: Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed therapy before treatment is initiated.
Must be free of systemic infection:\r\n* Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection\r\n* Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
Known infection requiring the systemic use of, for example, an antibiotic or antiviral agent
Current active infection requiring systemic antibiotic or antifungal therapy
Infection requiring intravenous antibiotic use within one week of enrollment.
Subjects must not have a known active infection requiring intravenous antibiotic therapy
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
DONOR: Evidence of infection not responding to antibiotic therapy
Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment
Has an active infection requiring intravenous antibiotic therapy
Any antibiotic therapy or evidence of infection within 1 week of registration
Active infection requiring intravenous (IV) antibiotic usage within the last week prior to the dosimetry portion of the study
Infection requiring current intravenous antibiotic therapy; the PI will serve as the final arbiter regarding eligibility
Evidence of active infection requiring antibiotic therapy ? 14 days prior to the first dose of PRTX- 100
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
Patients who have evidence of active infection that requires antibiotic therapy; patients must have been off antibiotic treatment for at least 3 weeks prior to initiating treatment and must be confirmed to be clear of the infection; if patient develops an infection requiring antibiotic treatment while on the treatment portion of the study patients will be treated for the active infection with antibiotics and will resume vaccine treatment when the infection is healed
Has an active infection requiring systemic therapy NOTE: Antibiotic therapy must have been completed a minimum of 3 days prior to start of study treatment;
Current use of antibiotic rinses or troches
Active systemic infection requiring parenteral antibiotic therapy
Has uncontrolled active infection of any kind. (Patients with infections controlled by active antibiotic treatment are eligible).
Infection requiring intravenous antibiotic use within 1 week.
Concurrent serious infections (i.e., requiring an intravenous antibiotic)
Active infection requiring IV antibiotic usage within the last week prior to study treatment
Infection requiring intravenous antibiotic use within 1 week.
Requires hospitalization for IV empiric antibiotic therapy
Has an active infection requiring systemic therapy; prior to dosing with REGN2810 the subject must be at least 5 half-lives from their last dose of antibiotic
Evidence of ongoing or active infection requiring antibiotic therapy
Active infection requiring systemic antibiotic therapy.
Acute/chronic infections, open wounds, or any active infection requiring intravenous antibiotic therapy =< 12 weeks prior to registration
Any active infection requiring antibiotic therapy within 2 weeks of study day 1.
No active systemic infection requiring parenteral antibiotic therapy
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
An infection requiring antibiotic treatment within seven days of starting study treatment (day -1)
Active infection requiring systemic antibiotic therapy.
Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
No active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening
Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5°F or 38.1°C) within 1 week prior to registration
Subjects with clinically serious infections requiring ongoing antibiotic therapy
Patients with infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study; patients on prophylactic antibiotics or antivirals are acceptable.
Active infection requiring systemic antibiotic therapy
Any antibiotic therapy or evidence of infection within 1 week of registration
Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment
Patients with active infection requiring systemic therapy or who are dependent on or currently receiving antibiotics that cannot be discontinued before dosing; (Note: subjects who discontinue an antibiotic prior to dosing must wait at least 5 half-lives after the last dose of antibiotic before receiving any ADXS11-001 infusion)
Current infections requiring antibiotic therapy.
Requires hospitalization for intravenous (IV) empiric antibiotic therapy
Concurrent serious infection requiring parenteral antibiotic therapy.
Patients requiring intravenous (IV) antiviral or IV antibiotic treatment for ongoing infections
Patients requiring IV antiviral or IV antibiotic treatment for ongoing infections
Known active infection requiring antibiotic treatment before the start of treatment (day 0)
Concurrent serious infections requiring parenteral antibiotic therapy.
Active systemic infection requiring systemic antibiotic treatment within 72 hours prior to first dose of study treatment
Receiving antibiotic therapy within 14 days before the first dose of study treatment
any infection requiring antibiotic, anticoagulant, or antiplatelet agents within the past 4 weeks
Active infection requiring antibiotic treatment
Active infection requiring antibiotic therapy
Any evidence of serious active, uncontrolled infection (i.e., requiring an IV antibiotic or antiviral agent)
Be receiving quinolone antibiotic therapy
Planned continuous antibiotic treatment during RT
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
Patients undergoing active antibiotic therapy
Planned continuous antibiotic treatment during RT
Require antibiotic therapy prior to oral cleaning
Patient is receiving antibiotic therapy for an active infection
Known active infection requiring antibiotic treatment
Active infection requiring systemic IV antibiotic therapy
Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not a prohibited medication
have an active infection requiring antibiotic therapy, or concomitant malignancies
